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ABSTRACT
We report the first results from a phase II, open-label study
designed to evaluate the efficacy and safety of bevacizumab in
combination with trastuzumab and capecitabine as first-line
therapy for human epidermal growth factor receptor (HER)-
2-positive locally recurrent (LR) or metastatic breast cancer
(MBC). Patients were aged>18 years with confirmed breast
adenocarcinoma, measurable LR/MBC and documented
HER-2-positive disease. Patients received bevacizumab (15
mg/kg on day 1) plus trastuzumab (8 mg/kg on day 1 of cycle
1, 6 mg/kg on day 1 of each subsequent cycle) plus capecit-
abine (1,000 mg/m2 twice daily, days 1–14) every 3 weeks until
disease progression, unacceptable toxicity, or consent with-
drawal. Eighty-eight patients were enrolled; 40 (46%) are still
on study treatment. The median follow-up was 8.8 months
(range, 0.9–17.1 months). The overall response rate, the pri-
mary endpoint, was 73% (95% confidence interval [CI],
62%–82%), comprising 7% complete and 66% partial re-
sponses. The median progression-free survival interval was
14.4 months (95% CI, 10.4 months to not reached [NR]), with
35 events. The median time to progression was 14.5 months
(95% CI, 10.5 months to NR), with 33 events. Treatment was
well tolerated; main side effects were grade 3 hand–foot syn-
drome (22%), grade>3 diarrhea (9%), and grade>3 hyper-
tension (7%). Overall, 44% of patients experienced grade>3
treatment-related adverse events and 13 patients discontin-
ued capecitabine because of toxicity, but continued with bev-
acizumab and trastuzumab. Heart failure was seen in two
patients. The combination of bevacizumab, trastuzumab, and
capecitabine was clinically active as first-line therapy for pa-
tients with HER-2-positive MBC, with an acceptable safety
profile and no unexpected toxicities. The Oncologist 2012;17:
469–475
INTRODUCTION
Patients with human epidermal growth factor receptor
(HER)-2– overexpressing metastatic breast cancer (MBC)
present with an aggressive course of disease that requires
effective first-line treatment. The humanized monoclonal
anti–HER-2 antibody trastuzumab, in combination with ei-
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ther docetaxel or paclitaxel, is the standard of care in this
setting [1, 2]. Novel agents and combination regimens are
continually sought that offer better efficacy and tolerability
than existing therapies.
Vascular endothelial growth factor (VEGF) plays a key
role in tumor-mediated angiogenesis [3]. Findings from pre-
clinical studies have provided the rationale for combining
agents that target both the HER-2 and VEGF receptor signal-
ing pathways [4–7]. Overexpression of HER-2 is associated
with greater VEGF expression in human breast cancer xeno-
grafts and greater angiogenic potential [5, 6]. Furthermore, a
significant association between HER-2 and VEGF expression
(p .001) was demonstrated in patients with early breast can-
cer, which was shown to predict outcome with therapy [8]. Re-
cent findings on the classification of breast cancer subtypes
also indicate the importance of VEGF pathways in patients
with HER-2–enriched tumors [9]. Bevacizumab is a human-
ized monoclonal antibody that recognizes and binds to all iso-
forms of VEGF [10]. Capecitabine has shown modest activity
in patients with chemotherapy- and trastuzumab-resistant
HER-2-positive MBC [11, 12].
In preclinical human breast cancer models, the in vivo an-
titumor activity of combined trastuzumab and capecitabine
was at least additive in terms of tumor growth inhibition and
tumor growth delay, compared with either agent alone [13].
Greater in vivo antitumor activity was also shown with the
combination of bevacizumab and trastuzumab versus the indi-
vidual agents in a human breast cancer xenograft model [7].
Similarly, synergistic effects were seen with capecitabine and
bevacizumab in a breast cancer xenograft model—longer tu-
mor growth inhibition and a longer life span were observed
with the combination regimen than with either agent alone
(p  .05) [14]. Several clinical trials in patients with MBC
have also demonstrated efficacy with doublet combinations of
trastuzumab, bevacizumab, and capecitabine, with acceptable
and manageable safety profiles, both in the first-line setting
and in later lines [11, 15–17].
We conducted the current study to investigate a nontaxane-
containing, triple-combination regimen of bevacizumab plus
trastuzumab and capecitabine as first-line therapy for patients
with HER-2-positive locally recurrent (LR) or MBC in a phase
II setting. Here, we report first efficacy and safety results from
the study.
METHODS
Patients
The study (ClinicalTrials.gov identifier, NCT00811135) was
carried out in accordance with the principles of Good Clinical
Practice and the Declaration of Helsinki. The protocol and sub-
sequent amendments were approved by the institutional re-
view board or ethics committee of each investigational site.
Written informed consent was obtained from each patient prior
to any study-related procedure.
Eligible patients were aged 18 years with confirmed
breast adenocarcinoma and measurable, LR, or metastatic le-
sions (according to the Response Evaluation Criteria in Solid
Tumors [RECIST]). Patients were required to have central lab-
oratory documented HER-2-positive disease (immunohisto-
chemistry 3 and/or fluorescence in situ hybridization
positive and/or chromogenic in situ hybridization positive) and
known estrogen receptor and progesterone receptor status. An
Eastern Cooperative Oncology Group performance status
score2 and adequate bone marrow reserve and liver and re-
nal function were also required. All patients were candidates
for chemotherapy.
Previous chemotherapy for LR/MBC was not permitted,
but prior neoadjuvant or adjuvant chemotherapy, hormone
therapy, or trastuzumab was allowed. Previous anthracycline
treatment must not have reached a maximum cumulative dose
360 mg/m2 of doxorubicin or720 mg/m2 of epirubicin and
must have been completed6 months before study enrolment.
Patients were excluded in the event of another primary tumor
5 years prior to enrolment (except adequately treated cervi-
cal cancer in situ, squamous cell skin cancer, or adequately
controlled basal cell cancer), central nervous system metasta-
ses, uncontrolled hypertension, or clinically significant cardio-
vascular disease.
Study Design
In this single-arm, open-label, multicenter, phase II study, pa-
tients received bevacizumab plus trastuzumab plus capecit-
abine in 21-day cycles until disease progression, unacceptable
toxicity, or withdrawal of consent. Trastuzumab was given as a
loading dose of 8 mg/kg on day 1 of the first cycle, followed by
a maintenance dose of 6 mg/kg on day 1 of each subsequent
cycle. Bevacizumab was administered at a dose of 15 mg/kg on
day 1, and capecitabine was administered at a dose of 1,000
mg/m2 twice daily, days 1–14. Doses were selected based on
common clinical practice and results of previous clinical trials
with these agents [18, 19]. Dose modification (interruptions,
adjustments, or discontinuations) of capecitabine was permit-
ted for toxicity; dose administration of trastuzumab or bevaci-
zumab could be delayed but no dose modifications for toxicity
were allowed.
The primary objective of the study was to assess the best
overall response rate (ORR) (according to investigator-re-
ported RECIST), defined as the percentage of patients with a
complete or partial response. Secondary objectives were to as-
sess progression-free survival (PFS), overall survival (OS),
time to progression (TTP), and safety (according to the Na-
tional Cancer Institute Common Terminology Criteria for Ad-
verse Events, version 3.0) outcomes. Post-treatment follow-up
occurs every 3 months until disease progression (tumor and ad-
verse event [AE] assessments) and for at least 24 months for
survival follow-up.
Statistical Analysis
The primary efficacy analysis was conducted in the intent-to-
treat (ITT) population (all enrolled patients who received at
least one dose of any study medication) and was repeated in the
per-protocol (PP) population (all eligible patients who re-
ceived at least one cycle of study treatment, had at least one
postbaseline tumor assessment, and did not have any major
protocol violation). Only results for the ITT population are pre-
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sented in this manuscript. Safety analyses were conducted in
all patients who received at least one dose of any study medi-
cation. The primary analysis was performed using a data cutoff
date of July 31, 2010 after a median follow-up 8.8 months
(range, 0.9–17.1 months). The study will end, and the final
analysis will be performed, when the death rate in the ITT pop-
ulation is80%. Updated PFS analyses and final OS analyses
will be performed at the end of the study.
Responders were defined as patients with a best overall re-
sponse of either a complete response or a partial response. The
number and percentage of patients with a best overall response
was summarized, and corresponding exact Clopper Pearson
95% confidence intervals (CIs) were calculated. Time-to-
event endpoints, that is, OS, TTP, and PFS, were analyzed us-
ing Kaplan–Meier methods. The median time to event with its
corresponding 95% CI, upper and lower quartiles, and event-
free rates were estimated from the Kaplan–Meier approach.
To test the null hypothesis that the study treatment con-
ferred a response proportion0.550 versus the alternative hy-
pothesis that the study treatment conferred a response
proportion0.700 at a 5% significance level, 70 evaluable pa-
tients were required to achieve a power of 80%. Assuming a
20% dropout rate,88 patients were to be enrolled.
RESULTS
Patients
From December 29, 2008 to January 11, 2010, 88 patients were
enrolled (ITT population). Forty patients (46%) were still on
study treatment at the time of this primary analysis. Two pa-
tients were excluded from the PP population, one as a result of
major protocol violations (failure of two inclusion criteria) and
the other because of missing postbaseline tumor assessments
(that patient died shortly after entering the study and was
classed as a study failure). The median patient age was 53.0
years (range, 32.0–82.0 years) and the majority of patients had
MBC (84.1%) and visceral disease (69.3%) (Table 1). Overall,
51 patients (58.0%) had received chemotherapy in the (neo)ad-
juvant setting and 22 patients (25.0%) had received (neo)adju-
vant trastuzumab and/or lapatinib.
Treatment Exposure
The median duration of trastuzumab therapy was 8.4 months
(range, 0.7–16.6 months). Treatment exposure was slightly
shorter for bevacizumab and capecitabine, at 7.7 months
(range, 0.7–16.6 months) and 7.6 months (range, 0.5–16.4
months), respectively. Two thirds of the patients completed
more than eight cycles of trastuzumab (69%), bevacizumab
(67%), or capecitabine (64%) therapy. Thirteen patients
stopped capecitabine therapy but continued with bevacizumab
and trastuzumab.
Efficacy Outcomes
The median follow-up time was 8.8 months (range, 0.9–17.1
months). The primary endpoint, best ORR, was 73% in the ITT
population (95% CI, 62%–82%), comprising 7% of patients
with complete responses and 66% of patients with partial re-
sponses. A further 16% of patients achieved stable disease as
their best response. Subgroup analyses of the ORR are shown
in Table 2.
The median PFS interval was 14.4 months (95% CI, 10.4
months to not reached [NR]), with 35 events (Fig. 1). The me-
dian TTP was 14.5 months (95% CI, 10.5 months to NR), with
33 events. The median OS time had not been reached, with a
12-month survival rate of 95.1% with four events to date. Pa-
tients previously treated with trastuzumab and/or lapatinib in
the (neo)adjuvant setting showed efficacy comparable with
that of the ITT population, with an ORR of 68% (95% CI,
45%–86%) and a median PFS interval and TTP of 14.8 months
each (Table 3).
Safety
Treatment-related AEs were reported by 92% of patients (n
81); treatment-related grade 3 AEs occurred in 44% of pa-
tients (n 39) (Table 4). Hand–foot syndrome (HFS) was the
most frequently reported grade 3 treatment-related AE, in 22%
of patients. Grade3 treatment-related diarrhea and hyperten-
sion were reported in 9% and 7% of patients, respectively.
Overall, 22% of patients (n  19) experienced a serious AE
Table 1. Baseline demographic and disease
characteristics (intent-to-treat population)
Characteristic Total (n 88)
Sex, n (%)
Male 1 (1.1)
Female 87 (98.9)
Median (range) age, yrs 53.0 (32.0–82.0)
Age category, n (%)
60 yrs 61 (69.3)
60 yrs 27 (30.7)
Metastatic breast cancer,a n (%) 74 (84.1)
Locally recurrent disease,a n (%) 13 (14.8)
Visceral,b n (%) 61 (69.3)
Nonvisceral, n (%) 27 (30.7)
Estrogen receptor or progesterone
receptor, n (%)
Positive 37 (42.0)
Other 51 (58.0)
Pretreated in the (neo)adjuvant
setting, n (%)
With chemotherapy 51 (58.0)
With a taxane 28 (31.8)
With trastuzumab and/or lapatinib 22 (25.0)
With radiotherapy 40 (45.5)
aOne patient had neither metastatic breast cancer nor
locally recurrent disease and was not included in
the per-protocol population.
bOf 61 patients, 34 had lung/liver organ site recorded as
target or nontarget, but not as both.
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(Table 5), with diarrhea and cardiac failure each occurring in
two patients. Serious treatment-related AEs were coded for
15% of patients (n  13); diarrhea occurred in two patients,
hematologic events and alopecia were rare.
Grade 3 cardiac failure was reported in a 50-year-old female
and was considered probably related to study treatment. That pa-
tient received 12 cycles each of bevacizumab, capecitabine, and
trastuzumab, but no prior chemotherapy, radiotherapy, or anti-
neoplastic agents for breast cancer. Her pretreatment visit left
ventricular ejection fraction was 60% and no cardiac abnormali-
ties were detected by electrocardiogram. She withdrew from the
study as a result of the cardiac failure. A 53-year-old female died
as a result of treatment-unrelated renal failure, and also experi-
enced treatment-unrelated cardiac failure.
In total, 19 patients (22%) withdrew prematurely from the
study. Eight patients (9%) discontinued for administrative or
other reasons, including mastectomy (n  5), patient and in-
vestigator decision (n 2), and withdrawal of consent (n 1).
Five patients (6%) withdrew as a result of AEs or intercurrent
illness, three patients (3%) died, and one patient withdrew as a
result of disease progression (1%). A further two patients dis-
continued prematurely (one violation of selection criteria and
one protocol violation). At the time of this primary analysis, 84
patients were still alive. Four treatment-unrelated deaths oc-
curred; these were recorded as disease progression (n 2), re-
spiratory failure (n 1), and cause unknown (n 1).
DISCUSSION
This single-arm, phase II study evaluated the efficacy and
safety of bevacizumab in combination with trastuzumab and
capecitabine as first-line therapy for HER-2-positive LR/
MBC. First results from the study showed the regimen to be
clinically active, with an ORR of 72.7% and a median PFS
time and TTP of 14.4 months and 14.5 months, respectively.
The median OS time had not yet been reached. Efficacy com-
Table 2. Subgroup analyses of ORR
Subgroup
n of
patients
ORR,
%
Complete
response, %
Partial
response, %
ORR 95% confidence
interval
Aged60 yrs 25 68.0 8.0 60.0 47–85
Metastatic breast cancer 74 73.0 6.8 66.2 61–83
Locally recurrent disease 13 76.9 7.7 69.2 46–95
ER positive or PgR positive 37 70.3 5.4 64.9 53–84
ER negative or PgR negative 51 74.5 7.8 66.7 60–86
Visceral 61 70.5 3.3 67.2 57–81
Nonvisceral 27 77.8 14.8 63.0 58–91
Chemotherapy naïvea 37 78.4 5.4 73.0 62–90
Chemotherapy pretreateda 51 68.6 7.8 60.8 54–81
aIn the (neo)adjuvant setting.
Abbreviations: ER, estrogen receptor; ORR, overall response rate; PgR, progesterone receptor.
Figure 1. Kaplan–Meier curve of progression-free survival (in-
tent-to-treat population).
Table 3. Efficacy outcomes in patients pretreated with
(neo)adjuvant trastuzumab and/or lapatinib and in ITT
patients
Outcome
Patients
pretreated
with
trastuzumab
and/or
lapatinib
(n 22)
ITT
population
(n 88)
Overall response,
% (95% CI)
68.2 (45–86) 72.7 (62–82)
Complete response 9.1 6.8
Partial response 59.1 65.9
Progression-free
survival events, n
9 35
Median, mos
(95% CI)
14.8 (8.2–14.8) 14.4 (10.4-NR)
Time to progression
events, n
8 33
Median, mos
(95% CI)
14.8 (8.2–14.8) 14.5 (10.5-NR)
Abbreviations: CI, confidence interval; ITT, intent-to-
treat; NR, not reached.
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parable with that of the ITT population was observed in pa-
tients previously treated with (neo)adjuvant trastuzumab
and/or lapatinib, who comprised 25% of the study population.
This confirms the benefit of continued treatment with trastu-
zumab in patients who have previously progressed while re-
ceiving this agent and supports the use of trastuzumab in
multiple lines [20]. In light of the low number of events, the
median PFS interval and median TTP cannot be robustly esti-
mated. The safety profile of the regimen was consistent with
prior clinical trials of the individual drugs, with HFS (22%)
and diarrhea (9%) being the most frequently reported grade3
treatment-related AEs. There was a relatively high rate of dis-
continuation from capecitabine treatment (n  13); however,
the triple-combination regimen was well tolerated overall.
Compared with other triple regimens investigated for HER-2-
positive MBC, patients in our study experienced considerably
less febrile neutropenia, neutropenia, and alopecia, whereas
the incidences of HFS and diarrhea were similar across the
studies [21, 22].
The combination of trastuzumab and capecitabine with an
antiangiogenic agent represents a novel therapeutic approach
for the first-line treatment of HER-2-positive MBC. Trastu-
zumab has exhibited clinical activity for both adjuvant [23]
and first-line metastatic [1, 2] HER-2-positive breast cancer, as
well as in subsequent lines [11, 20, 24]. In two randomized,
phase II trials, first-line trastuzumab plus paclitaxel or do-
cetaxel led to a significantly longer OS time, higher ORR, and
longer TTP than with a taxane alone [1, 2]. Extensive clinical
experience with trastuzumab shows it to be generally well tol-
erated, with mild-to-moderate infusion-related reactions re-
ported most frequently [25]. Capecitabine offers the
convenience of oral dosing and has a well-established safety
profile that lacks myelosuppression and alopecia, with AEs
readily managed by dose modification [26].
A number of studies have demonstrated the high clinical
activity of capecitabine in combination with anti–HER-2
agents in MBC patients. The German Breast Group 26/Breast
International Group 03–05 phase III trial randomized patients
with HER-2-positive MBC that had progressed during prior
trastuzumab therapy to receive trastuzumab with or without
capecitabine (n  156) [11]. A significantly greater ORR
(48.1% versus 27.0%, respectively; odds ratio [OR], 2.50; p
.0115) and TTP (median, 8.2 months versus 5.6 months, re-
spectively; hazard ratio [HR], 0.69; p .0338) were observed
in patients who continued trastuzumab in combination with
capecitabine than in those receiving capecitabine alone. The
incidence and severity of AEs were comparable between the
treatment arms, with the exception of grade 1–4 anemia, which
was more frequent in the trastuzumab arm (64%, versus 44%
with capecitabine alone; p .021). Geyer et al. [12] compared
the combination of lapatinib and capecitabine with capecit-
abine alone in a randomized, phase III trial in patients with
HER-2-positive MBC previously treated with an anthracy-
cline, a taxane, and trastuzumab (n 399). A significantly lon-
Table 4. Treatment-related AEs occurring in2% of
patients
AE
Total
n 88
(%)
Grade>3
n 88
(%)
Patients with at least one AE 81 (92) 39 (44)
Cardiac disorders 5 (6) 2 (2)
Gastrointestinal disorders 49 (56) 10 (11)
Diarrhea 33 (38) 8 (9)
General disorders, administration
site conditions
40 (46) 3 (3)
Infections and infestations 11 (13) 2 (2)
Respiratory, thoracic, and
mediastinal disorders
33 (38) 2 (2)
Skin and s.c. tissue disorders 66 (75) 19 (22)
Hand–foot syndrome 62 (71) 19 (22)
Vascular disorders 31 (35) 7 (8)
Hypertension 28 (32) 6 (7)
Abbreviation: AE, adverse event.
Table 5. Serious AEs and serious treatment-related AEs
Total (n 88)
Serious AE
Total,
n (%)
Treatment-related,
n (%)
Patients with at least one
serious AE
19 (22) 13 (15)
Diarrhea 2 (2) 2 (2)
Cardiac failure (or cardiac
failure acute)
2 (2) 1 (1)
Intracardiac thrombus 1 (1) 1 (1)
Abdominal pain 1 (1) 1 (1)
Enteritis 1 (1) 1 (1)
Mesentric artery embolism 1 (1) 1 (1)
Peritonitis 1 (1) 0
Chest pain 1 (1) 1 (1)
Death 1 (1) 0
Erysipelas 1 (1) 1 (1)
Pneumonia 1 (1) 0
Abdominal wound
dehiscence
1 (1) 0
Fall 1 (1) 0
Cerebral ischemia 1 (1) 1 (1)
Presyncope 1 (1) 1 (1)
Abortion, spontaneous 1 (1) 0
Hematuria 1 (1) 1 (1)
Renal failure 1 (1) 0
Dyspnea 1 (1) 0
Pulmonary embolism 1 (1) 1 (1)
Respiratory failure 1 (1) 0
Abbreviation: AE, adverse event.
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ger TTP (median, 6.2 months versus 4.3 months, respectively;
HR, 0.57; 95% CI, 0.43–0.77; p  .001) and a higher ORR
(23.7% versus 13.9%, respectively; OR, 1.90; p .017) were
achieved in patients receiving the combination regimen than in
those receiving single-agent capecitabine [27]. Diarrhea, HFS,
and nausea were the most common AEs across both treatment
groups. The high clinical activity of trastuzumab plus capecit-
abine combination therapy was also reported in three single-
arm, phase II studies as first-line (n  63) and later lines of
treatment (n  74) in HER-2-positive MBC patients [16, 17,
28]. In the first-line setting, ORRs were60%, with a median
TTP of 9.2 months and median OS time of 25.6 months
[16, 17].
A number of clinical trials have demonstrated the efficacy
of doublet combinations of trastuzumab, bevacizumab, and
capecitabine in patients with MBC [11, 15–17]. Pegram et al.
[15] assessed the combination of trastuzumab and bevaci-
zumab as first-line therapy for HER-2-positive MBC and
found clinical benefit in 31 of 37 patients, with complete re-
sponses in one of 37 patients and partial responses in 19 of 37
patients. Definitive data on the combination of trastuzumab
plus bevacizumab in the first-line setting will be provided
by the phase III AVastin in combination with hERceptin/
docetaxEL in HER-2-positive MBC (AVEREL) trial; final re-
sults are expected at the end of 2011.
Because anthracyclines and taxanes are increasingly used
in the (neo)adjuvant setting, an increasing proportion of pa-
tients are presenting with MBC who require a nonanthracy-
cline- and nontaxane-containing first-line regimen. First
efficacy and safety data from our study indicate that the com-
bination of bevacizumab with trastuzumab and capecitabine is
feasible as first-line therapy for patients with HER-2-positive
MBC and warrants further investigation. The final analysis is
expected in 2012. Although the recent decision by the U.S.
Food and Drug Administration to revoke its approval for bev-
acizumab for the treatment of MBC may reduce interest in this
drug, or in this triple combination, new trials in breast cancer
are ongoing and the results are eagerly awaited.
CONCLUSIONS
The triple-combination regimen of trastuzumab, bevacizumab,
and capecitabine appears to be clinically active as first-line
therapy for patients with HER-2-positive MBC, with an ac-
ceptable safety profile and no unexpected toxicities. Patients
previously treated with (neo)adjuvant trastuzumab and/or
lapatinib also showed favorable efficacy and safety outcomes.
This regimen merits further evaluation in a randomized, phase
II trial versus a taxane plus trastuzumab standard combination.
ACKNOWLEDGMENTS
This study was sponsored by F. Hoffmann-La Roche, Ltd. The
authors would like to thank Severine Wollenschneider and
Anja-Alexandra Duenne for their help in the preparation of this
manuscript.
The authors take full responsibility for the content of the
paper but thank Fiona Fernando (Gardiner-Caldwell Commu-
nications, supported by F. Hoffmann-La Roche Ltd.) for her
medical writing support.
These data were previously presented at the 47th Annual
Meeting of the American Society of Clinical Oncology, Chi-
cago, IL, June 3–7, 2011.
AUTHOR CONTRIBUTIONS
Conception/Design: Ana Lluch, Vladimir Semiglazov, Nana Scotto, Lada
Mitchell, Sergei Tjulandin, Mikhail Lichinitser, Joseph Gligorov, Anatoly
Makhson, Miguel Martín
Provision of study material or patients: Ana Lluch, Vladimir Semiglazov,
Sergei Tjulandin, Mikhail Lichinitser, Joseph Gligorov, Anatoly Makhson,
Miguel Martín
Collection and/or assembly of data: Ana Lluch, Vladimir Semiglazov, Nana
Scotto, Lada Mitchell, Sergei Tjulandin, Mikhail Lichinitser, Joseph
Gligorov, Anatoly Makhson, Miguel Martín
Data analysis and interpretation: Ana Lluch, Vladimir Semiglazov, Nana
Scotto, Lada Mitchell, Sergei Tjulandin, Mikhail Lichinitser, Joseph
Gligorov, Anatoly Makhson, Miguel Martín
Manuscript writing: Miguel Martín
Final approval of manuscript: Ana Lluch, Vladimir Semiglazov, Nana
Scotto, Lada Mitchell, Sergei Tjulandin, Mikhail Lichinitser, Joseph
Gligorov, Anatoly Makhson, Miguel Martín
REFERENCES
1. Slamon DJ, Leyland-Jones B, Shak S et al. Use
of chemotherapy plus a monoclonal antibody
against HER2 for metastatic breast cancer that
overexpresses HER2. N Engl J Med 2001;344:
783–792.
2. Marty M, Cognetti F, Maraninchi D et al. Ran-
domized phase II trial of the efficacy and safety of
trastuzumab combined with docetaxel in patients
with human epidermal growth factor receptor 2-pos-
itive metastatic breast cancer administered as first-
line treatment: The M77001 study group. J Clin
Oncol 2005;23:4265–4274.
3. Ferrara N. Role of vascular endothelial growth
factor in physiologic and pathologic angiogenesis:
Therapeutic implications. Semin Oncol 2002;
29(suppl 16):10–14.
4. Petit AM, Rak J, Hung MC et al. Neutralizing
antibodies against epidermal growth factor and
ErbB-2/neu receptor tyrosine kinases down-regulate
vascular endothelial growth factor production by tu-
mor cells in vitro and in vivo: Angiogenic implica-
tions for signal transduction therapy of solid tumors.
Am J Pathol 1997;151:1523–1530.
5. Epstein M, Ayala RE, Tchekmedyian N et al.
HER2-overexpressing human breast cancer xeno-
grafts exhibit increased angiogenic potential medi-
ated by vascular endothelial growth factor (VEGF)
[abstract 570]. Breast Cancer Res Treat 2002;
76(suppl 1):S143.
6. Yen L, You XL, Al Moustafa AE et al. Heregulin
selectively upregulates vascular endothelial growth
factor secretion in cancer cells and stimulates angio-
genesis. Oncogene 2000;19:3460–3469.
7. Scheuer W, Friess T, Hasmann M. Enhanced an-
titumor effect by combination of HER2-targeting an-
tibodies with bevacizumab in a human breast cancer
xenograft model [abstract 213]. Eur J Cancer Suppl
2006;4:66.
8. Konecny GE, Meng YG, Untch M et al. Associ-
ation between HER-2/neu and vascular endothelial
growth factor expression predicts clinical outcome in
primary breast cancer patients. Clin Cancer Res
2004;10:1706–1716.
9. Prat A, Perou CM. Deconstructing the molecular
portraits of breast cancer. Mol Oncol 2011;5:5–23.
10. Ferrara N, Hillan KJ, Gerber HP et al. Discov-
ery and development of bevacizumab, an anti-VEGF
antibody for treating cancer. Nat Rev Drug Discov
2004;3:391–400.
11. von Minckwitz G, du Bois A, Schmidt M et al.
Trastuzumab beyond progression in human epider-
mal growth factor receptor 2-positive advanced
breast cancer: A German Breast Group 26/Breast In-
ternational Group 03–05 study. J Clin Oncol 2009;
27:1999–2006.
12. Geyer CE, Forster J, Lindquist D et al. Lapa-
tinib plus capecitabine for HER2-positive advanced
breast cancer. N Engl J Med 2006;355:2733–2743.
13. Fujimoto-Ouchi K, Sekiguchi F, Tanaka Y. An-
titumor activity of combinations of anti-HER-2 anti-
body trastuzumab and oral fluoropyrimidines
capecitabine/5-dFUrd in human breast cancer mod-
els. Cancer Chemother Pharmacol 2002;49:211–
216.
14. Higgins B, Kolinsky K, Linn M et al. Antitumor
474 Bevacizumab Plus Trastuzumab and Capecitabine for MBC
activity of capecitabine and bevacizumab combina-
tion in a human estrogen receptor-negative breast ad-
enocarcinoma xenograft model. Anticancer Res
2007;27:2279–2287.
15. Pegram M, Chan D, Dichmann RA et al. Phase
II combined biological therapy targeting the HER2
proto-oncogene and the vascular endothelial growth
factor using trastuzumab (T) and bevacizumab (B) as
first line treatment of HER2-amplified breast cancer
[abstract 301]. Breast Cancer Res Treat 2006;
100(suppl 1):S28.
16. Xu L, Song S, Zhu J et al. Capecitabine tras-
tuzumab as first-line treatment in patients with
HER2-positive metastatic breast cancer (MBC):
Phase II trial results [abstract 2065]. Breast Cancer
Res Treat 2006;100(suppl 1):S101.
17. Yamamoto D, Iwase S, Kitamura K et al. A
phase II study of trastuzumab and capecitabine for
patients with HER2-overexpressing metastatic
breast cancer: Japan Breast Cancer Research Net-
work (JBCRN) 00 Trial. Cancer Chemother Pharma-
col 2008;61:509–514.
18. Cobleigh MA, Langmuir VK, Sledge GW et al.
A phase I/II dose-escalation trial of bevacizumab in
previously treated metastatic breast cancer. Semin
Oncol 2003;30(suppl 16):117–124.
19. Leyland-Jones B, Gelmon K, Ayoub JP et al.
Pharmacokinetics, safety, and efficacy of trastu-
zumab administered every three weeks in combina-
tion with paclitaxel. J Clin Oncol 2003;21:3965–
3971.
20. Lang I, Bell R, Feng-Yi F et al. Trastuzumab
use at relapse after adjuvant trastuzumab therapy in
HER2-positive breast cancer. J Clin Oncol 2011;
29(15 suppl):575.
21. Wardley AM, Pivot X, Morales-Vasquez F et
al. Randomized phase II trial of first-line trastu-
zumab plus docetaxel and capecitabine compared
with trastuzumab plus docetaxel in HER2-positive
metastatic breast cancer. J Clin Oncol 2010;28:976–
983.
22. Chan A, Ganju V, Becquart D et al. High effi-
cacy of the combination of oral vinorelbine (NVBo),
capecitabine (X) and trastuzumab (H) in HER2-pos-
itive metastatic breast cancer (MBC): Updated re-
sults of an international phase II trial with a median
follow-up of 39 months [abstract P-5055]. Eur J Can-
cer Suppl 2009;7:276.
23. Yin W, Jiang Y, Shen Z et al. Trastuzumab in
the adjuvant treatment of HER2-positive early breast
cancer patients: A meta-analysis of published ran-
domized controlled trials. PLoS One 2011;6:e21030.
24. Mannocci A, De Feo E, de Waure C et al. Use of
trastuzumab in HER2-positive metastatic breast can-
cer beyond disease progression: A systematic review
of published studies. Tumori 2010;96:385–391.
25. Smith IE. Efficacy and safety of Herceptin in
women with metastatic breast cancer: Results from
pivotal clinical studies. Anticancer Drugs 2001;
12(suppl 4):S3–S10.
26. Leonard R, Hennessy BT, Blum JL et al. Dose-
adjusting capecitabine minimizes adverse effects
while maintaining efficacy: A retrospective review
of capecitabine for metastatic breast cancer. Clin
Breast Cancer 2011;11:349–356.
27. Cameron D, Casey M, Press M et al. A phase III
randomized comparison of lapatinib plus capecit-
abine versus capecitabine alone in women with ad-
vanced breast cancer that has progressed on
trastuzumab: Updated efficacy and biomarker anal-
yses. Breast Cancer Res Treat 2008;112:533–543.
28. Ishida T, Kiba T, Takeda M et al. Phase II study
of capecitabine and trastuzumab combination che-
motherapy in patients with HER2 overexpressing
metastatic breast cancers resistant to both anthracy-
clines and taxanes. Cancer Chemother Pharmacol
2009;64:361–369.
475Martín, Makhson, Gligorov et al.
www.TheOncologist.com
